Jamie Kasuboski
Fondateur chez Avilar Therapeutics, Inc.
Profil
Jamie is a Vice President with OMX Ventures.
Prior to OMX Jamie developed deep experience in early-stage Biotech investing and company creation while working on the investment team at RA Capital.
In that role he served on the board of Enara Bio, Avilar Therapeutics, and Endor Therapeutics.
Before joining RA, he was a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired by Merck & Co.) and Rewind Therapeutics.
Education: PhD in Molecular and Cellular Biology from the University of Notre Dame and a BS in Biology with a minor in Chemistry from Hillsdale College
Postes actifs de Jamie Kasuboski
| Sociétés | Poste | Début |
|---|---|---|
| ReAx Biotechnologies | Directeur/Membre du Conseil | 01/12/2021 |
| Seeker Biologics, Inc. | Directeur/Membre du Conseil | 01/09/2021 |
Glyphic Biotechnologies Inc
 Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | Directeur/Membre du Conseil | 01/04/2021 |
| Chicago Biomedical Consortium | Consultant / Advisor | 01/04/2022 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Fondateur | 01/11/2019 |
Anciens postes connus de Jamie Kasuboski
| Sociétés | Poste | Fin |
|---|---|---|
Omx Ventures LLC
 Omx Ventures LLC Investment ManagersFinance OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois. | Private Equity Investor | 01/02/2024 |
| Enara Bio Ltd. | Directeur/Membre du Conseil | 01/02/2021 |
ReWind Therapeutics NV
 ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Directeur/Membre du Conseil | 01/09/2019 |
Boehringer Ingelheim Venture Fund
 Boehringer Ingelheim Venture Fund Investment ManagersFinance Boehringer Ingelheim Venture Fund is an evergreen venture capital fund which seeks investment opportunities in biotech across the globe. It targets investments unrelated to Boehringer Ingelheim’s key therapeutic areas. Specifically, it focuses on start-up companies engaging in patient care enhancements through pioneering science including new therapeutic platforms, new generation vaccines, and new generation protein & antibody technologies, among others. The fund makes initial equity investments of EUR 500 thousand to EUR 3 million in seed or series A rounds. It also makes follow-on investments over a five to seven year time period, bringing the total investment size per company to an amount of EUR 10 million to EUR 15 million. The fund seeks to acquire minority stakes (usually greater than or equal to 10%) in target companies, as well as a seat on the board. | Private Equity Investor | 01/09/2019 |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Jamie Kasuboski
| University of Notre Dame | Doctorate Degree |
| Hillsdale College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund Investment ManagersFinance Boehringer Ingelheim Venture Fund is an evergreen venture capital fund which seeks investment opportunities in biotech across the globe. It targets investments unrelated to Boehringer Ingelheim’s key therapeutic areas. Specifically, it focuses on start-up companies engaging in patient care enhancements through pioneering science including new therapeutic platforms, new generation vaccines, and new generation protein & antibody technologies, among others. The fund makes initial equity investments of EUR 500 thousand to EUR 3 million in seed or series A rounds. It also makes follow-on investments over a five to seven year time period, bringing the total investment size per company to an amount of EUR 10 million to EUR 15 million. The fund seeks to acquire minority stakes (usually greater than or equal to 10%) in target companies, as well as a seat on the board. | Finance |
Tilos Therapeutics, Inc.
 Tilos Therapeutics, Inc. BiotechnologyHealth Technology Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA. | Health Technology |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Health Technology |
| Chicago Biomedical Consortium | |
Omx Ventures LLC
Omx Ventures LLC Investment ManagersFinance OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois. | Finance |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
Glyphic Biotechnologies Inc
Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | Commercial Services |
| Enara Bio Ltd. | Health Technology |
| ReAx Biotechnologies | Health Technology |
| Seeker Biologics, Inc. |
